Be proactive when co-managing patients

Article

Co-management relationships with ophthalmologists differ from community to community, but it's often best for the optometrist to take a proactive role in the pre-and postoperative decision-making and care.

Key Points

Salt Lake City-Co-management relationships with ophthalmologists differ from community to community, but it's often best for the optometrist to take a proactive role in the pre- and postoperative decision-making and care, according to Paul C. Ajamian, OD, FAAO, at the annual meeting of the American Optometric Association.

"Make sure patients are aware that you're in a co-management relationship with a surgeon, and that they're in agreement with doing that. Most patients want to see their OD for post-op care, once you explain how it works," he noted.

A two-way street

The doctor-to-doctor relationship also needs to be fostered. Let the surgeon know about any pertinent findings that may affect outcomes, such as blepharitis or medication use. It's better to recommend delaying surgery for a few weeks while you treat a problem such as dry eye rather than send the patient in with a condition that could affect the post-op acuity, he said.

Optometrists also must learn the surgeon's preoperative and postoperative protocols.

"You want to look like a team," said Dr. Ajamian, adding that the optometrist should spend time in the surgeon's office and be present during at least one surgery session to become familiar with the medications used and instructions given to the patient.

"It means a lot to patients when you can tell them exactly what will happen on surgery day because you witnessed it yourself," he explained.

"The best marketing you can ever do is to scrub in with your patient. Patients appreciate the effort and may be more comfortable if they sense that their optometrist is more than a passive bystander. If the surgeon doesn't welcome you, there's something wrong," he added.

Remember that co-management is a two-way street, and the surgeon has responsibilities to the optometrist, Dr. Ajamian said.

First, the surgeon must provide a consent form indicating the patient's willingness to have the optometrist provide postoperative care. The surgeon is expected to inform the optometrist if problems arose during surgery. If you've been briefed, you won't be caught off guard if a patient returns to you with 20/200 corneal edema; you will be able to reassure the patient that you can manage the situation.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.